HCG liquid, 1000u/ml, RX, glass vial, various
Published January 9, 2019 · Recall initiated: January 2, 2019
Summary
FDA records drug Class II recall D-0395-2019, published January 9, 2019 and initiated January 2, 2019. Recalling firm: Hiers Enterprises, LLC dba Northwest Compounding Pharmacy; Status: Terminated; Reported quantity: 30 ml; Lot: 10162018@22. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of sterility assurance.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Hiers Enterprises, LLC dba Northwest Compounding Pharmacy
- Distributor
- Product was distributed exclusively in the state of Oregon to 3 Medical facilities, 1 Physician's office and 80 consumers/patients. These are compounded products - labels vary for each compound - specific to each patient. Firm did not provide labeling.
- Lot
- 10162018@22
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMethocarbamol liquid 100mg/ml, RX, glass vialJanuary 9, 2019
- FDALidocaine gel 2%, RX, plastic dropperJanuary 9, 2019
- FDAHydroxyprogesterone liquid, 250mg/ml, RX, glass vialJanuary 9, 2019
- FDAGlutathione liquid, 200mg/ml, RxJanuary 9, 2019
- FDAABL800 analyzer, model numbers 393-800 and 393-801.January 2, 2019
- FDAHydroSet XT Injectable HA Bone Cement, REF 897003, STERILEJanuary 2, 2019
Questions about this recall
Was HCG liquid, 1000u/ml, RX, glass vial, various recalled?
Yes. FDA published recall D-0395-2019 on January 9, 2019. Reported hazard: Lack of sterility assurance.
What should I do if I have this product?
Voluntary: Firm initiated · Letter